Corporate Presentation January 2017

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, Trillium's ability to obtain financing to advance the products in its development portfolio; changing market conditions; the successful and timely completion of pre- clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in Trillium's ongoing quarterly and annual reporting. Forward-looking statements are made only as of the date of this presentation and except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investment Highlights

  • Immuno-oncology company developing a next generation checkpoint inhibitor, engaging multiple arms of the immune system

  • Lead program targets CD47, a "do not eat" signal tumor cells exploit to escape destruction by the immune system

  • Phase 1a trial in patients with relapsed/refractory lymphomas completed; Phase 1b enrolling 10 cohorts of advanced hematologic malignancies

  • Second trial in solid tumors is currently recruiting and additional trials planned

  • Proprietary fluorine-based medicinal chemistry platform generating a pipeline of pre-clinical oncology assets

Trillium Pipeline: A Clinical Focus on CD47 Blockade with a Platform for Generating New Oncology Assets

SIRPαFc (CD47 Blockade)

TTI-621 (Systemic)

Discovery Preclinical Phase 1 Phase 2 Hematological malignancies

TTI-621 (Intratumoral)

Solid tumors + mycosis fungoides

Fluorine Med Chem Platform

Bromodomain Inhibitor TBD EGFR Inhibitor High brain penetration for glioblastoma & brain mets Undisclosed Targets

4

Trillium Therapeutics Inc. published this content on 25 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 January 2017 17:12:10 UTC.

Original documenthttp://s2.q4cdn.com/772010778/files/doc_presentations/2017/Trillium-Corp-Deck-Jan-2017-with-Reformatted-Figures.pdf

Public permalinkhttp://www.publicnow.com/view/B5F351586B1EFD9FAF27EBBB29259907C9BBEA4D